Higher productivity, lower hold times, lower costs… continuous processing for monoclonal antibodies could offer a number of advantages.

We only have one planet. We must play a responsible role when it comes to its care.

Can’t offer an “affordable” price? Then say goodbye to market exclusivity.

Industry experts share how their therapeutic products are shaping the future of the pharmaceutical landscape.

Is the regulator environment changing fast enough to accommodate the vast array of microbiome-based therapeutics beginning to emerge?

Looking for an experienced partner to simplify the development and manufacture of a new antibody-drug conjugate (ADC)?

Some have dismissed excitement about the microbiome as “hype,” but real results are beginning to be seen.

Nominations for The Medicine Maker 2019 will close on Friday, October 25.

David Donabedian of Axial Biotherapuetics explains the role of the microbiome in the onset of Parkinson's Disease and autism.

Joe Biden apparently dared say there were “great drug companies out there – except for a couple of opioid outfits.”